These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3519413)

  • 1. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
    Dimitriadis G; Karaiskos C; Raptis S
    Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
    Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
    J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
    Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
    Hayakawa T; Noda A; Kondo T; Okumura N
    Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modification of carbohydrate metabolism and oral glucose tolerance test in type II diabetics using the glucosidase inhibitor acarbose].
    Schwartzkopff W; Calder D
    Med Welt; 1984 Feb; 35(6):169-74. PubMed ID: 6369065
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
    Robertson J; Nelson R; Kass P; Neal L
    Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
    Bischoff H
    Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].
    Fölsch UR; Lembcke B
    Internist (Berl); 1991 Dec; 32(12):699-707. PubMed ID: 1823561
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic potential of alpha-glucosidase-inhibitors.
    Fölsch UR
    Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
    Yamamoto M; Otsuki M
    Metabolism; 2006 Apr; 55(4):533-40. PubMed ID: 16546485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
    Dimitriadis GD; Tessari P; Go VL; Gerich JE
    Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
    Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acarbose--a new therapeutic principle in diabetes mellitus therapy].
    Schöffling K; Hillebrand I
    Dtsch Med Wochenschr; 1981 Aug; 106(35):1083-4. PubMed ID: 6114844
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of acarbose as monotherapy in NIDDM patients.
    Deerochanawong C; Serirat S; Kornthong P
    J Med Assoc Thai; 1996 Feb; 79(2):69-75. PubMed ID: 8868016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an alpha-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats.
    Yamashita K; Sugawara S; Sakairi I
    Horm Metab Res; 1984 Apr; 16(4):179-82. PubMed ID: 6373545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acarbose, an unduly neglected antidiabetic drug].
    Iványi J; Gyimesi A
    Orv Hetil; 1996 Dec; 137(49):2737-41. PubMed ID: 9679608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.